Quick Overview: Scott T. Tagawa, MD, MS, Weill Cornell Medical College, New York Presbyterian Hospital, NY, discusses the results of a ... Scott Tagawa, FACP, MD, MS, Weill Cornell Medicine, New York, NY, provides an overview of the Steven Horwitz, MD, PhD, Memorial Sloan-Kettering Cancer Center, New York, NY, reports updates from the first-in-human

Phase I Ii Dose Escalation - Detailed Overview & Context

Scott T. Tagawa, MD, MS, Weill Cornell Medical College, New York Presbyterian Hospital, NY, discusses the results of a ... Scott Tagawa, FACP, MD, MS, Weill Cornell Medicine, New York, NY, provides an overview of the Steven Horwitz, MD, PhD, Memorial Sloan-Kettering Cancer Center, New York, NY, reports updates from the first-in-human Scott Tagawa, MD, MS, FACP, Weill Cornell Medical Center, New York, NY, discusses the Gary Schiller, MD, University of California, Los Angeles, Los Angeles, CA, outlines findings of a In this video, a Principal Investigator explains what a

The UMB-DF/HCC PArtnership's Research Design and Analysis Core (RDAC) held a seminar on October 27, 2022 featuring ... Presented by Dr. Barbara Wendelberger. Proper Hang Quach, MBBS(Hons), SpecCertOC, FRACP, FRCPA, MD, St. Vincent's Hospital & University of Melbourne, Melbourne, ... Patrick Schöffski, MD, MPH, KU Leuven, Leuven, Belgium, talks on a In this video we look at the issues around designing In this video, David Sallman, MD, Moffitt Cancer Center, Tampa, FL, comments on the promising results of a

Watch as Steven Pipe discusses BeCoMe–9: A James Harding, MD, Memorial Sloan Kettering Cancer Center, New York, NY, provides an overview of a A concise overview of how chemotherapy dosing is optimized—from Innovations in statistics, programming and data management are changing the very nature of clinical development. East® ESCALATE is the new East software module to design, simulate, and operationally support

Photo Gallery

Phase I/II dose-escalation study of 225Ac-J591 in progressive mCRPC
Phase I dose-escalation study of fractionated dose 225Ac J591 for mCRPC
TTI-621 for hematologic malignancies: a Phase I dose escalation and expansion study
A phase I/II dose-escalation study of fractionated dose 177Lu-PSMA-617 for progressive mCRPC
Phase I dose-escalation study of zelavespib in patients with relapsed myelofibrosis
Clinical Trials: A Principal Investigator Explains Dose Escalation, Phase by Phase.
What Is Dose Escalation In Phase 1 Clinical Trials? - Trials and Treatments Uncovered
Design of Adaptive Phase 1 Clinical Trials for Dose Escalation using the DEDUCE Application
NHLBI ICTR SHORT VIDEO #6: DOSE SELECTION
Designs of dose escalation studies in phase I oncology trials
A Phase I, first-in-human study of ISB 2001 in R/R myeloma: dose escalation results
Phase I dose-escalation and expansion study evaluating BI 907828 in patients with solid tumours
Sponsored
Sponsored
View Main Result
Sponsored
Sponsored